Αυστραλία - Αγγλικά - APVMA (Australian Pesticides and Veterinary Medicines Authority)

zoetis australia pty ltd - haemophilus parasuis (serovar 5) strain 1a84-29755 - unknown - haemophilus parasuis (serovar 5) strain 1a84-29755 vaccine-microbial active 0.0 - active constituent

Καναδάς - Αγγλικά - Health Canada

aventis pasteur limited - haemophilus influenzae type b-prp; diphtheria toxoid - liquid - 25mcg; 23mcg - haemophilus influenzae type b-prp 25mcg; diphtheria toxoid 23mcg - vaccines

Καναδάς - Αγγλικά - Health Canada

merck manufacturing division, division of merck & co., inc. - haemophilus influenzae type b-prp; neisseria meningitidis outer membrane protein complex - powder for solution - 15mcg; 250mcg - haemophilus influenzae type b-prp 15mcg; neisseria meningitidis outer membrane protein complex 250mcg - vaccines

Αυστραλία - Αγγλικά - APVMA (Australian Pesticides and Veterinary Medicines Authority)

zoetis australia pty ltd - haemophilus parasuis; thiomersal - misc. vaccines or anti sera - haemophilus parasuis vaccine active 0.0 p; thiomersal mercury other 0.1 mg/ml - immunotherapy - pigs | boar | gilt | piglet | sow | swine - glassers disease | haemophilus parasuis serovar 13 | haemophilus parasuis serovar 4 | haemophilus parasuis serovar 5 | polyserositis

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

remedyrepack inc. - ceftriaxone sodium (unii: 023z5br09k) (ceftriaxone - unii:75j73v1629) - before instituting treatment with ceftriaxone for injection, usp, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. therapy may be instituted prior to obtaining results of susceptibility testing. to reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftriaxone for injection, usp and other antibacterial drugs, ceftriaxone for injection, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. ceftriaxone for injection, usp is indicated for the treatment of the following infections when caused by susceptible organisms: lower respiratory tract infections caused by streptococcus pneumoniae, staphylococcus aureus, haemophilus influenzae, haemophilus parainfluenzae, klebsiella pneumoniae, escherichia coli, enterobacter aerogenes, proteus mirabilis or serratia marcescens. acute bacterial otitis media caused by streptococcus pneumoniae, haemophilus influenzae (including beta-lactamase producing strains) or moraxella catarrhalis (including beta-lactamase producing strains). note: in one study lower clinical cure rates were observed with a single dose of ceftriaxone for injection, usp compared to 10 days of oral therapy. in a second study comparable cure rates were observed between single dose ceftriaxone for injection, usp and the comparator. the potentially lower clinical cure rate of ceftriaxone for injection, usp should be balanced against the potential advantages of parenteral therapy (see clinical studies ). skin and skin structure infections caused by staphylococcus aureus, staphylococcus epidermidis, streptococcus pyogenes , viridans group streptococci, escherichia coli, enterobacter cloacae, klebsiella oxytoca, klebsiella pneumoniae, proteus mirabilis, morganella morganii,* pseudomonas aeruginosa, serratia marcescens, acinetobacter calcoaceticus, bacteroides fragilis* or peptostreptococcus species. urinary tract infections (complicated and uncomplicated) caused by escherichia coli, proteus mirabilis, proteus vulgaris, morganella morganii or klebsiella pneumoniae. uncomplicated gonorrhea (cervical/urethral and rectal) caused by neisseria gonorrhoeae, including both penicillinase- and nonpenicillinase-producing strains, and pharyngeal gonorrhea caused by nonpenicillinase-producing strains of neisseria gonorrhoeae. pelvic inflammatory disease caused by neisseria gonorrhoeae. ceftriaxone for injection, usp, like other cephalosporins, has no activity against chlamydia trachomatis . therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and chlamydia trachomatis is one of the suspected pathogens, appropriate antichlamydial coverage should be added. bacterial septicemia caused by staphylococcus aureus, streptococcus pneumoniae, escherichia coli, haemophilus influenzae or klebsiella pneumoniae. bone and joint infections caused by staphylococcus aureus, streptococcus pneumoniae, escherichia coli, proteus mirabilis, klebsiella pneumoniae or enterobacter species. intra-abdominal infections caused by escherichia coli, klebsiella pneumoniae, bacteroides fragilis, clostridium species (note: most strains of clostridium difficile are resistant) or peptostreptococcus species. meningitis caused by haemophilus influenzae, neisseria meningitidis or streptococcus pneumoniae. ceftriaxone for injection, usp has also been used successfully in a limited number of cases of meningitis and shunt infection caused by staphylococcus epidermidis* and escherichia coli.* * efficacy for this organism in this organ system was studied in fewer than ten infections. surgical prophylaxis: the preoperative administration of a single 1 g dose of ceftriaxone for injection, usp may reduce the incidence of postoperative infections in patients undergoing surgical procedures classified as contaminated or potentially contaminated (eg , vaginal or abdominal hysterectomy or cholecystectomy for chronic calculous cholecystitis in high-risk patients, such as those over 70 years of age, with acute cholecystitis not requiring therapeutic antimicrobials, obstructive jaundice or common duct bile stones) and in surgical patients for whom infection at the operative site would present serious risk (eg , during coronary artery bypass surgery). although ceftriaxone for injection, usp has been shown to have been as effective as cefazolin in the prevention of infection following coronary artery bypass surgery, no placebo-controlled trials have been conducted to evaluate any cephalosporin antibiotic in the prevention of infection following coronary artery bypass surgery. when administered prior to surgical procedures for which it is indicated, a single 1 g dose of ceftriaxone for injection, usp provides protection from most infections due to susceptible organisms throughout the course of the procedure. ceftriaxone for injection is contraindicated in patients with known hypersensitivity to ceftriaxone, any of its excipients or to any other cephalosporin. patients with previous hypersensitivity reactions to penicillin and other beta lactam antibacterial agents may be at greater risk of hypersensitivity to ceftriaxone (see warnings – hypersensitivity ). premature neonates : ceftriaxone for injection is contraindicated in premature neonates up to a postmenstrual age of 41 weeks (gestational age + chronological age). hyperbilirubinemic neonates : hyperbilirubinemic neonates should not be treated with ceftriaxone for injection. ceftriaxone can displace bilirubin from its binding to serum albumin, leading to a risk of bilirubin encephalopathy in these patients. ceftriaxone for injection is contraindicated in neonates (≤ 28 days) if they require (or are expected to require) treatment with calcium-containing iv solutions, including continuous calcium-containing infusions such as parenteral nutrition because of the risk of precipitation of ceftriaxone-calcium (see clinical pharmacology, warnings and dosage and administration ). cases of fatal outcomes in which a crystalline material was observed in the lungs and kidneys at autopsy have been reported in neonates receiving ceftriaxone for injection and calcium-containing fluids. in some of these cases, the same intravenous infusion line was used for both ceftriaxone for injection and calcium-containing fluids and in some a precipitate was observed in the intravenous infusion line. there have been no similar reports in patients other than neonates. intravenous administration of ceftriaxone solutions containing lidocaine is contraindicated. when lidocaine solution is used as a solvent with ceftriaxone for intramuscular injection, exclude all contraindications to lidocaine. refer to the prescribing information of lidocaine.

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

estreno pharmaceuticals, llc - clarithromycin (unii: h1250jik0a) (clarithromycin - unii:h1250jik0a) - clarithromycin tablets, clarithromycin for oral suspension and clarithromycin extended-release tablets are indicated in adults for the treatment of mild to moderate infections caused by susceptible isolates due to haemophilus influenzae , haemophilus parainfluenzae , moraxella catarrhalis , or streptococcus pneumoniae [see indications and usage (1.9)] . clarithromycin tablets, clarithromycin for oral suspension and clarithromycin extended-release tablets (in adults) are indicated for the treatment of mild to moderate infections caused by susceptible isolates due to haemophilus influenzae , moraxella catarrhalis , or streptococcus pneumoniae [see indications and usage (1.9)] . clarithromycin tablets, clarithromycin for oral suspension and clarithromycin extended-release tablets are indicated [see indications and usage (1.9)] for the treatment of mild to moderate infections caused by susceptible isolates due to: - haemophilus influenzae (in adults) - haemophilus parainfluenzae (clarithromycin extended-rele

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - clarithromycin (unii: h1250jik0a) (clarithromycin - unii:h1250jik0a) - clarithromycin 500 mg - clarithromycin tablets, usp are indicated in adults for the treatment of mild to moderate infections caused by susceptible isolates due to haemophilus influenzae , haemophilus parainfluenzae , moraxella catarrhalis , or streptococcus pneumoniae [see indications and usage (1.9)] . clarithromycin tablets, usp are indicated for the treatment of mild to moderate infections caused by susceptible isolates due to haemophilus influenzae , moraxella catarrhalis , or streptococcus pneumoniae [see indications and usage (1.9)] . clarithromycin tablets, usp are indicated [see indications and usage (1.9)] for the treatment of mild to moderate infections caused by susceptible isolates due to: - haemophilus influenzae (in adults) - mycoplasma pneumoniae , streptococcus pneumoniae , chlamydophila pneumoniae clarithromycin tablets, usp are indicated for the treatment of mild to moderate infections caused by susceptible isolates due to streptococcus pyogenes as an alternative in individuals who cannot use first line ther

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

merus labs international inc. - gemifloxacin mesylate (unii: x4s9f8rl01) (gemifloxacin - unii:okr68y0e4t) - gemifloxacin 320 mg - factive is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions listed below. (see dosage and administration and clinical studies. ) acute bacterial exacerbation of chronic bronchitis (abecb) caused by streptococcus pneumoniae, haemophilus influenzae, haemophilus parainfluenzae, or moraxella catarrhalis . because fluoroquinolones, including factive, have been associated with serious adverse reactions (see warnings ) and for some patients abecb is self-limiting, reserve factive for treatment of abecb in patients who have no alternative treatment options. community-acquired pneumonia (of mild to moderate severity) caused by streptococcus pneumoniae (including multi-drug resistant strains [mdrsp])*, haemophilus influenzae, moraxella catarrhalis, mycoplasma pneumoniae, chlamydia pneumoniae, or klebsiella pneumoniae . *mdrsp: multi-drug resistant s

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

oscient pharmaceuticals - gemifloxacin mesylate (unii: x4s9f8rl01) (gemifloxacin - unii:okr68y0e4t) - tablet - 320 mg - factive is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions listed below. (see dosage and administration and clinical studies . ) acute bacterial exacerbation of chronic bronchitis caused by streptococcus pneumoniae, haemophilus influenzae, haemophilus parainfluenzae, or moraxella catarrhalis . community-acquired pneumonia (of mild to moderate severity) caused by streptococcus pneumoniae (including multi-drug resistant strains [mdrsp])*, haemophilus influenzae, moraxella catarrhalis, mycoplasma pneumoniae, chlamydia pneumoniae, or klebsiella pneumoniae . *mdrsp: multi-drug resistant streptococcus pneumoniae , includes isolates previously known as prsp (penicillin-resistant streptococcus pneumoniae ), and are strains resistant to two or more of the following antibiotics: penicillin (mic ≥2 μg/ml), 2nd generation cephalosporins (e.g., cefuroxime), macrolides, tetracyclines and trimethoprim/sulfamethoxazole. to reduce the development

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

legacy pharmaceutical packaging - ciprofloxacin hydrochloride (unii: 4ba73m5e37) (ciprofloxacin - unii:5e8k9i0o4u) - ciprofloxacin 500 mg - ciprofloxacin tablets are indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions and patient populations listed below. please see dosage and administration for specific recommendations. urinary tract infections caused by escherichia coli, klebsiella pneumoniae, enterobacter cloacae, serratia marcescens, proteus mirabilis, providencia rettgeri, morganella morganii, citrobacter diversus, citrobacter freundii, pseudomonas aeruginosa, methicillin-susceptible staphylococcus epidermidis, staphylococcus saprophyticus, or enterococcus faecalis. acute uncomplicated cystitis in females caused by escherichia coli or staphylococcus saprophyticus . chronic bacterial prostatitis caused by escherichia coli or proteus mirabilis . lower respiratory tract infections caused by escherichia coli , klebsiella pneumoniae , enterobacter cloacae , proteus mirabilis , pseudomonas aeruginosa , haemophilus influenzae , haemophilus parainfluenzae , or peni